Tan Eng King

Institution
National Neuroscience Institute

Country
Singapore

Field
Life Sciences

Tan Eng King received the 2018 President’s Science Award for identifying clinical biomarkers, developing novel models and transforming patient care in Parkinson’s Disease. (Photo: National Neuroscience Institute)


Related articles

WHO Warns Of Rising Anti-Malarial Drug Resistance In Asia

Growing resistance to artemisinin is threatening to roll back gains made in combating the disease, said malaria experts at a health conference in Sydney, Australia last week.

Asian Scientist Chats With Prof. Warwick Anderson, CEO Of Australia’s NHMRC

At the recent A*STAR-NHMRC joint symposium, Asian Scientist Magazine sat down for a chat with Prof. Warwick Anderson, CEO of Australia’s National Health and Medical Research Council.

Asia Braces For Ebola: Is Biotech Our Best Bet?

Juliana Chan & Yamini Chinnuswamy take a look at the options available in our medical toolbox should Ebola reach our shores.

Chinese Researchers Pinpoint Origins Of H7N9 Avian Flu

Chinese researchers have identified the origins of the novel H7N9 influenza virus that has led to 109 human infections and 22 deaths in China.

Studying Animals To Improve Human Health

Research into animals, both common and obscure, are yielding insights into human health that are not always expected, writes Shuzhen Sim.

Influenza Virus Breaks Through Protective Mucus Net During Infection

Researchers have shown how influenza A viruses snip through a protective mucus net to both infect respiratory cells and later cut their way out to infect other cells.

Small Non-Coding RNAs Can Cross The Placenta, Scientists Say

Researchers claim that small exogenous RNAs from plants eaten by a mother can cross the placenta and affect fetal development.

Experts Discuss Latest In Hematology Research At Suntec Singapore

Hematology experts gathered at Suntec Singapore from March 29-30, 2014 to discuss the latest in blood disorders research.

Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection

A late-stage clinical trial has shown that Sanofi's dengue vaccine reduces dengue hemorrhagic fever by 89 percent but does not protect against serotype 2.